Mendus Future Growth
Future criteria checks 5/6
Mendus is forecast to grow earnings and revenue by 52.8% and 58.4% per annum respectively while EPS is expected to grow by 70.7% per annum.
Key information
52.8%
Earnings growth rate
70.7%
EPS growth rate
Biotechs earnings growth | 40.8% |
Revenue growth rate | 58.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 May 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -38 | -38 | -38 | 1 |
12/31/2025 | 264 | 390 | 390 | 390 | 2 |
12/31/2024 | 2 | -131 | -88 | -88 | 2 |
3/31/2024 | 31 | -107 | -163 | -160 | N/A |
12/31/2023 | 28 | -102 | -165 | -163 | N/A |
9/30/2023 | 1 | -104 | -189 | -187 | N/A |
6/30/2023 | 1 | -116 | -91 | -91 | N/A |
3/31/2023 | 1 | -141 | -123 | -119 | N/A |
12/31/2022 | 3 | -139 | -122 | -109 | N/A |
9/30/2022 | 2 | -128 | -124 | -114 | N/A |
6/30/2022 | 2 | -117 | -126 | -114 | N/A |
3/31/2022 | 2 | -119 | -123 | -114 | N/A |
12/31/2021 | 0 | -133 | -139 | -138 | N/A |
9/30/2021 | N/A | -148 | -130 | -129 | N/A |
6/30/2021 | N/A | -138 | -112 | -111 | N/A |
3/31/2021 | 0 | -119 | -91 | -90 | N/A |
12/31/2020 | N/A | -89 | -57 | -57 | N/A |
9/30/2020 | 16 | 3 | 11 | 13 | N/A |
6/30/2020 | 16 | -11 | -7 | -5 | N/A |
3/31/2020 | 17 | -31 | -22 | -21 | N/A |
12/31/2019 | 17 | -48 | -58 | -58 | N/A |
9/30/2019 | 0 | -118 | -114 | -114 | N/A |
6/30/2019 | 0 | -112 | -102 | -102 | N/A |
3/31/2019 | N/A | -98 | -89 | -89 | N/A |
12/31/2018 | N/A | -98 | -105 | -105 | N/A |
9/30/2018 | N/A | -90 | -88 | -88 | N/A |
6/30/2018 | N/A | -89 | -89 | -89 | N/A |
3/31/2018 | N/A | -88 | -94 | -94 | N/A |
12/31/2017 | N/A | -80 | N/A | -46 | N/A |
9/30/2017 | N/A | -86 | N/A | -76 | N/A |
6/30/2017 | N/A | -77 | N/A | -75 | N/A |
3/31/2017 | N/A | -72 | N/A | -68 | N/A |
12/31/2016 | N/A | -61 | N/A | -59 | N/A |
9/30/2016 | N/A | -48 | N/A | -51 | N/A |
6/30/2016 | N/A | -44 | N/A | -40 | N/A |
3/31/2016 | N/A | -37 | N/A | -33 | N/A |
12/31/2015 | N/A | -38 | N/A | -35 | N/A |
9/30/2015 | N/A | -37 | N/A | -37 | N/A |
6/30/2015 | N/A | -36 | N/A | -40 | N/A |
3/31/2015 | N/A | -33 | N/A | -33 | N/A |
12/31/2014 | N/A | -28 | N/A | -24 | N/A |
9/30/2014 | N/A | -21 | N/A | -18 | N/A |
6/30/2014 | N/A | -16 | N/A | -9 | N/A |
3/31/2014 | N/A | -13 | N/A | -11 | N/A |
12/31/2013 | N/A | -10 | N/A | -10 | N/A |
9/30/2013 | N/A | -8 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMMU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: IMMU is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMMU is expected to become profitable in the next 3 years.
Revenue vs Market: IMMU's revenue (58.4% per year) is forecast to grow faster than the Swedish market (2.1% per year).
High Growth Revenue: IMMU's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMMU's Return on Equity is forecast to be high in 3 years time